Fate Therapeutics (FATE) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Fate Therapeutics Reports First Quarter 2014 Financial Results
May 13, 2014 4:01 PM EDTPhase 2 PUMA Study of PROHEMA® in Adult Hematologic Malignancies Enrolling Patients
Phase 1b PROMPT Study of PROHEMA in Pediatric Hematologic Malignancies Cleared by FDA
IND Submission for Study of PROHEMA in Rare Genetic Disorders Expected in 2Q14
SAN DIEGO, May 13, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq: FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today reported clinical development updates and... More
